ERBB2 and neoplasm: In patients with ER/HER-2 co-positive tumours, median BMFS was 26 months (95% CI: 16.40–35.60) and therefore significantly longer than in patients with ER-negative/HER-2-positive disease (15 months; 95% CI: 10.77–19–23; P=0.033, log-rank test) (Figure 3).